Cancer BiologybioRxivPreprint
Disruption of NUAK2-Mediated RNA Splicing by Trilaciclib Reveals a Therapeutic Vulnerability in AR-Indifferent Prostate Cancer
Umar Mehraj, Uran Maimekov, Shaista Manzoor…·Everardo Macias
This paper identifies NUAK2 as a therapeutic target in AR-indifferent prostate cancer, showing trilaciclib inhibits NUAK2 and suppresses tumor growth.
DOI 10.1101/2025.11.12.687734